

## Combined Silencing of VEGF-A and Angiopoietin-2, a More Effective Way to Inhibit the Ishikawa Endometrial Cancer Cell Line [Retraction]

Xu X, Yan Y, Xun Q, et al. *Onco Targets Ther.* 2019;12:1215-1223.

We, the Editor and Publisher of the journal *OncoTargets and Therapy* have retracted the published article.

Following publication of the article, the authors raised concerns about the duplication of images from Figure 2. Specifically,

- The images for Figure 2D, siVEGF and siANG, have been duplicated.

The corresponding author was cooperative and responded to our queries but was unable to provide a satisfactory explanation for how the images came to be duplicated or provide satisfactory original data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, the Publisher and Editor requested to retract the article and the corresponding author was notified of this.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

### Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>